RTI gets $5M in patent dispute

Texas-based Retractable Technologies (NYSE AMEX: RVP) will recover $5 million with prejudgment interest from Becton, Dickinson after receiving a permanent injunction and an order in its patent litigation involving the 1- and 3-mL Integra syringes.

The U.S. District Court for the Eastern District of Texas, Marshall Division entered judgment for RTI and rejected BD's counter claims for declaratory judgment of non-infringement, invalidity, and unenforceability.

The court ordered a permanent injunction for the Integra syringes at issue until the expiration of certain patents. However, the permanent injunction is stayed for the longer of the exhaustion of an appeal of this case or 12 months from the date of the order, which is May 19, 2010, according to an RTI statement.

RTI  manufactures the VanishPoint automated retraction safety syringes, blood collection devices, and IV catheters, that virtually eliminate healthcare worker exposure to accidental needlestick injuries.

Shares of Retractable Technologies added 5 cents, or 3 percent, to $1.70 in afternoon trading. Becton Dickinson shares climbed 37 cents to $71.86, ABC News reports.

- get RTI's statement
- read ABC News' coverage

Suggested Articles

The U.S. regulator has given the green light to moderate-risk medical devices despite them not always meeting the FDA’s own standards.

Machine learning drug development company insitro has bought up Haystack Sciences, adding DNA-encoded libraries to its R&D arsenal.

IBM and Pfizer developed an artificial intelligence model that could eventually predict if a person will develop Alzheimer’s using a language test.